Novacyt S.A. (EPA:ALNOV)

Market Cap	33.00M
Revenue (ttm)	23.74M
Net Income (ttm)	-50.50M
Shares Out	70.54M
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,784
Average Volume	115,925
Open	0.4500
Previous Close	0.4679
Day's Range	0.4500 - 0.4680
52-Week Range	0.4185 - 1.5900
Beta	-0.04
RSI	43.54
Earnings Date	Apr 30, 2025

About Novacyt

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 234
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNOV

Financial Performance

In 2024, Novacyt's revenue was 19.63 million, an increase of 69.53% compared to the previous year's 11.58 million. Losses were -41.76 million, 47.6% more than in 2023.

Financial numbers in GBP